NCT01881867 - CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 10, 2013

Primary Completion Date

May 15, 2017

Study Completion Date

January 2, 2018

Conditions

Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer

Interventions

BIOLOGICAL

Glycosylated Recombinant Human Interleukin-7

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (16)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

27157

Wake Forest University Health Sciences, Winston-Salem

30322

Emory University/Winship Cancer Institute, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

92093

UC San Diego Moores Cancer Center, La Jolla

94115

UCSF Medical Center-Mount Zion, San Francisco

94158

UCSF Medical Center-Mission Bay, San Francisco

98109

Fred Hutchinson Cancer Research Center, Seattle

Seattle Cancer Care Alliance, Seattle

98195

University of Washington Medical Center, Seattle

02215

Dana-Farber Cancer Institute, Boston

03756

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors

collaborator

Cancer Immunotherapy Trials Network

NETWORK

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER